Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 4/20 | 0.64 |
| ▸ | HK1 | P19367 | 2/20 | 0.58 |
| ▸ | HK2 | P52789 | 2/20 | 0.58 |
| ▸ | PYGL | P06737 | 4/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| B-D-Galactose SCHEMBL27766291 | 0.88 | LGALS1 (0.52) | SLC5A2HK1HK2 | |
| Dextrose SCHEMBL28143229 | 0.88 | LGALS1 (0.52) | SLC5A2HK1HK2 | |
| Beta-D-Glucose SCHEMBL27745359 | 0.88 | LGALS1 (0.52) | SLC5A2HK1HK2 | |
| B-D-Galactose SCHEMBL28251165 | 0.88 | LGALS1 (0.52) | SLC5A2HK1HK2 | |
| Beta-D-Glucose SCHEMBL27816737 | 0.87 | TYR (0.53) | SLC5A2HK1HK2 | |
| Dextrose SCHEMBL28221975 | 0.87 | TYR (0.53) | SLC5A2HK1HK2 | |
| Dextrose SCHEMBL8638386 | 0.87 | SLC5A2 (0.58) | SLC5A2HK1HK2 | |
| Dextrose SCHEMBL3220374 | 0.86 | PYGL (0.49) | SLC5A2PYGL | |
| B-D-Galactose SCHEMBL15768434 | 0.86 | PYGL (0.49) | SLC5A2PYGL | |
| D-Mannose SCHEMBL28626185 | 0.85 | SLC5A2 (0.49) | SLC5A2HK1HK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3003322-B1 | MANNOSE DERIVATIVES AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTIONS | WASHINGTON UNIVERSITY ST LOUIS (US) | 2023-09-13 | — | — | EP | disclosed |
| US-20230033327-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | WASHINGTON UNIVERSITY | 2023-02-02 | — | — | US | disclosed |
| US-20210122776-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-04-29 | — | — | US | disclosed |
| US-20200368256-A1 | Treatment for Bacterial Infections | WASHINGTON UNIVERSITY (US) | 2020-11-26 | — | — | US | disclosed |
| CN-111423479-A | Compounds and methods for treating bacterial infections | 华盛顿大学 | 2020-07-17 | — | — | CN | disclosed |
| US-20190211045-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | UNIV WASHINGTON (US) | 2019-07-11 | — | — | US | disclosed |
| EP-3492483-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | The Washington University (US) | 2019-06-05 | — | — | EP | disclosed |
| US-10273260-B2 | Compounds and methods for treating bacterial infections | WASHINGTON UNIVERSITY (US) | 2019-04-30 | — | — | US | disclosed |
| EP-2672820-B1 | MANNOSIDE COMPOUNDS AND METHODS OF USE THEREOF | UNIV WASHINGTON (US) | 2019-04-17 | — | — | EP | disclosed |
| US-20180194792-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | WASHINGTON UNIVERSITY | 2018-07-12 | — | — | US | disclosed |
| EP-2672820-A1 | MANNOSIDE COMPOUNDS AND METHODS OF USE THEREOF | The Washington University (US) | 2013-12-18 | — | — | EP | disclosed |
| US-20120309701-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | THE WASHINGTON UNIVERSITY (US) | 2012-12-06 | — | — | US | disclosed |
| EP-2513128-A2 | MANNOSE DERIVATIVES AS ANTAGONISTS OF BACTERIAL ADHESION | University of Basel (CH) | 2012-10-24 | — | — | EP | disclosed |
| CN-102753562-A | Mannose derivatives as antagonists of bacterial adhesion | UNIV BASEL | 2012-10-24 | — | — | CN | disclosed |
| WO-2012125576-A1 | COMPOSITIONS AND METHODS FOR MODIFYING A SILICONE SURFACE FOR PROLONGED INTERFERENCE AGAINST PATHOGEN COLONOIZATION | UNIVERSITY OF HOUSTON (US) | 2012-09-20 | — | — | WO | disclosed |
| US-20120231518-A1 | COMPOSITIONS AND METHODS FOR MODIFYING A SILICONE SURFACE FOR PROLONGED INTERFERENCE AGAINST PATHOGEN COLONIZATION | UNIVERSITY OF HOUSTON (US) | 2012-09-13 | — | — | US | disclosed |
| EP-2490530-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | The Washington University (US) | 2012-08-29 | — | — | EP | disclosed |
| WO-2012109263-A1 | MANNOSIDE COMPOUNDS AND METHODS OF USE THEREOF | THE WASHINGTON UNIVERSITY (US) | 2012-08-16 | — | — | WO | disclosed |
| WO-2011073112-A2 | MANNOSE DERIVATIVES AS ANTAGONISTS OF BACTERIAL ADHESION | UNIVERSITY OF BASEL (CH) | 2011-06-23 | — | — | WO | disclosed |
| WO-2011050323-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | THE WASHINGTON UNIVERSITY (US) | 2011-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230033327-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | FPR1, VIL1, VIP | SLC5A2 1388/4885HK1 1169/4885HK2 2677/4885 |
| US-10273260-B2 | Compounds and methods for treating bacterial infections | MMP8, ELANE, GUSB | SLC5A2 835/4885HK1 603/4885HK2 527/4885 |
| US-20200368256-A1 | Treatment for Bacterial Infections | BPGM, BLVRB, LRBA | SLC5A2 3149/4885HK1 1154/4885HK2 1464/4885 |
| US-20120309701-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | MMP8, ELANE, GUSB | SLC5A2 835/4885HK1 603/4885HK2 527/4885 |
| US-20180194792-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | FPR1, VIL1, VIP | SLC5A2 1388/4885HK1 1169/4885HK2 2677/4885 |
| US-20210122776-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | FPR1, VIL1, VIP | SLC5A2 1388/4885HK1 1169/4885HK2 2677/4885 |
| US-20190211045-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | MMP8, ELANE, GUSB | SLC5A2 835/4885HK1 603/4885HK2 527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.